Journey Medical Corporation
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Journey Medical Corporation specializes in the acquisition, development, and commercialization of pharmaceutical products for dermatological conditions in the United States. Its product portfolio includes prescription drugs such as Qbrexza, a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin medication for severe recalcitrant nodular acne; Amzeeq, a topical minocycline formulation for inflammatory acne vulgaris; Zilxi, a topical minocycline treatment for rosacea; Exelderm, targeting fungal skin infections; Targadox, an oral doxycycline for severe acne adjunctive therapy; Emrosi, oral minocycline capsules for rosacea; and Luxamend, a water-based emulsion designed to promote moist healing of superficial wounds, minor burns, and radiation dermatitis. Founded in 2018 and headquartered in Scottsdale, Arizona, Journey Medical operates primarily within the U.S. pharmaceutical market, targeting healthcare providers and patients with dermatological needs. The company employs an efficient sales and marketing model led by a team with extensive dermatology industry experience. Recently, Journey Medical has focused on the successful launch and commercialization of Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules) following its FDA approval in November 2024, with initial prescriptions filled and full commercial promotion underway since April 2025. The launch has been supported by the publication of superior Phase 3 clinical trial results in the Journal of the American Medical Association Dermatology and inclusion in updated treatment guidelines for rosacea. Operationally, the company appointed Ramsey Alloush as Chief Operating Officer in April 2025 and continues to streamline expenses while maintaining a strong cash position. Journey Medical's strategic direction emphasizes expanding its dermatology portfolio through acquisitions and product development to achieve sustainable revenue growth and profitability. In summary, Journey Medical Corporation is a U.S.-based specialty pharmaceutical company focused on dermatology products including prescription medications for acne, rosacea, hyperhidrosis, and wound care, with recent major developments centered around the launch and commercial expansion of its Emrosi product and ongoing operational enhancements.
Journey Medical Corporation to Participate in A.G.P.'s Annual Virtual Healthcare Conference
Journey Medical Corporation (DERM) Q1 2026 Earnings Call Transcript
Journey Medical Corporation (DERM) Reports Q1 Loss, Beats Revenue Estimates
Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Journey Medical Corporation - DERM
Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026
Will Journey Medical Corporation (DERM) Report Negative Q1 Earnings? What You Should Know
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Journey Medical Corporation - DERM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Journey Medical Corporation - DERM
Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Journey Medical Corporation - DERM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Journey Medical Corporation - DERM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Journey Medical Corporation - DERM
Journey Medical Corporation Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Journey Medical Corporation (NASDAQ:DERM) Given Consensus Rating of “Hold” by Analysts
Journey Medical (DERM) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Journey Medical Corporation (DERM) Q4 2025 Earnings Call Transcript
Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026
Journey Medical (NASDAQ:DERM) Shares Down 3.5% – What’s Next?